NEED OF EXTERNAL QUALITY ASSESSMENT SCHEME – AN EXPERIENCE IN CENTRAL LABORATORY AT RNTMC, UDAIPUR

Pragya Jakhar, Vijay Rajak, Gunja Dwivedi, Kiran Meena
{"title":"NEED OF EXTERNAL QUALITY ASSESSMENT SCHEME – AN EXPERIENCE IN CENTRAL LABORATORY AT RNTMC, UDAIPUR","authors":"Pragya Jakhar, Vijay Rajak, Gunja Dwivedi, Kiran Meena","doi":"10.22159/ajpcr.2024.v17i6.50813","DOIUrl":null,"url":null,"abstract":"Objectives: The objectives of the study are to periodically assess the quality of the external quality assessment scheme (EQAS) with the aim of enhancing laboratory performances.\nMethods: An observational study was done at our central laboratory at RNTMC, Udaipur, after approval from the institutional review board. Our laboratory receives quarterly blood samples and already prepared slides from AIIMS, Delhi, for complete blood count (CBC). In addition, lyophilized blood samples for fibrinogen, prothrombin time/international normalized ratio (PT/INR), and activated partial thromboplastin time (APTT) analysis are received quarterly from CMC, Vellore, through courier package. As for cytopathology, the third package includes already prepared 10 slides of 2 cycles for cytopathology analysis along with a brief clinical history.\nResults: CBC, peripheral blood film examination findings, and reticulocyte count results were consistently acceptable, except in August 2021, December 2022, and March 2023 when some parameters of CBC were deemed unacceptable. Results for PT/INR, APTT, and fibrinogen were within consensus at all-time except in March 2022, when they were out within consensus and deemed unacceptable. Similarly, results for cytopathology evaluation were in concordance with the results of the provider except for a few occasions were deviations were seen for some diagnoses due to interpretation error.\nConclusion: Engaging in EQAS has facilitated the enhancement of test result accuracy, thereby improving the overall quality of laboratory practices and minimizing erroneous outcomes.","PeriodicalId":8528,"journal":{"name":"Asian Journal of Pharmaceutical and Clinical Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Journal of Pharmaceutical and Clinical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22159/ajpcr.2024.v17i6.50813","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: The objectives of the study are to periodically assess the quality of the external quality assessment scheme (EQAS) with the aim of enhancing laboratory performances. Methods: An observational study was done at our central laboratory at RNTMC, Udaipur, after approval from the institutional review board. Our laboratory receives quarterly blood samples and already prepared slides from AIIMS, Delhi, for complete blood count (CBC). In addition, lyophilized blood samples for fibrinogen, prothrombin time/international normalized ratio (PT/INR), and activated partial thromboplastin time (APTT) analysis are received quarterly from CMC, Vellore, through courier package. As for cytopathology, the third package includes already prepared 10 slides of 2 cycles for cytopathology analysis along with a brief clinical history. Results: CBC, peripheral blood film examination findings, and reticulocyte count results were consistently acceptable, except in August 2021, December 2022, and March 2023 when some parameters of CBC were deemed unacceptable. Results for PT/INR, APTT, and fibrinogen were within consensus at all-time except in March 2022, when they were out within consensus and deemed unacceptable. Similarly, results for cytopathology evaluation were in concordance with the results of the provider except for a few occasions were deviations were seen for some diagnoses due to interpretation error. Conclusion: Engaging in EQAS has facilitated the enhancement of test result accuracy, thereby improving the overall quality of laboratory practices and minimizing erroneous outcomes.
外部质量评估计划的必要性--乌达布尔 Rntmc 中央实验室的经验
研究目的本研究的目的是定期评估外部质量评估计划(EQAS)的质量,以提高实验室的绩效:在获得机构审查委员会批准后,我们在乌代布尔 RNTMC 的中心实验室开展了一项观察性研究。我们的实验室每季度从德里的 AIIMS 接收血液样本和已经制备好的切片,用于全血细胞计数(CBC)。此外,我们每季度还通过快递包裹从韦洛雷的 CMC 收到冻干血样,用于纤维蛋白原、凝血酶原时间/国际标准化比率(PT/INR)和活化部分凝血活酶时间(APTT)分析。至于细胞病理学,第三个包裹包括已经准备好的 10 张 2 个周期的切片,用于细胞病理学分析,以及简要的临床病史:结果:除了 2021 年 8 月、2022 年 12 月和 2023 年 3 月,全血细胞计数、外周血片检查结果和网织红细胞计数结果被认为不可接受外,其他时间的全血细胞计数、外周血片检查结果和网织红细胞计数结果均可接受。除了 2022 年 3 月,PT/INR、APTT 和纤维蛋白原的结果不在共识范围内,被认为不可接受之外,其他时间的结果均在共识范围内。同样,细胞病理学评估结果也与医疗服务提供者的结果一致,只有少数情况下由于解释错误导致某些诊断结果出现偏差:参与 EQAS 有助于提高检验结果的准确性,从而提高实验室工作的整体质量,最大限度地减少错误结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信